Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Biotechnology

Healthcare
$0.90 +3.01%

+$0.06 today

Market cap
$54.28M
Beta
1.19
P/E (TTM)
-4.2
EPS (TTM)
-$0.45
52W Low $1.07High $6.18

Volume 1.45M

Average 2.13M

ALDX Long-term Debt

Borrowings due after more than one year.

Aldeyra Therapeutics, Inc.NASDAQ: ALDX

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt remains negative

Q1 FY2026 long-term debt was $0, compared with $15.1M a year earlier.

Context

  • Long-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, down 16.2 pp from a year earlier.
  • Long-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
Year agoMar 2025
$15.1M-100.0% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Long-term Debt vs competitors

How ALDX compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -100.0% is the lowest of 5, against a peer median of +9.0%.
  • Long-term debt amounts to 0.0% of total assets for ALDX, versus a peer median of 0.3%.
ALDX Competitors
Long-term Debt for ALDX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CLLSCellectis S.A.Mar 2026$67.5M USD+47.6%+76.0%23.3%
KYTXKyverna Therapeutics, Inc.Mar 2026$24.81M USD——9.7%
AMRNAmarin Corporation plcMar 2026$5.59M USD-29.7%—0.9%
ANROAlto Neuroscience, Inc.Mar 2026$3.56M USD-83.2%-64.0%1.3%
CADLCandel Therapeutics, Inc.Mar 2026$1.34M USD+48.6%-58.8%0.7%
ALDXAldeyra Therapeutics, Inc.Mar 2026$0 USD-100.0%—0.0%
SLNSilence Therapeutics plcMar 2026$0 USD——0.0%
CTNMContineum Therapeutics, Inc. Class A Common StockMar 2026$0 USD——0.0%
ACIUAC Immune S.A.Mar 2026CHF 0 CHF——0.0%
GNLXGenelux CorporationMar 2026$0 USD——0.0%
MREOMereo BioPharma Group plcMar 2026$0 USD——0.0%
Peer median (excluding ALDX) —+9.0%-58.8%0.3%

Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents229.79M144.42M142.82M54.53M70.04M
Short-term Investments029.88M046.62M0
Net Receivables28.77K3.24M000
Inventory00000
Other Current Assets2.5M3.05M4.65M2.51M1.34M
Total Current Assets232.75M181.02M147.81M104.07M71.78M
Property, Plant & Equipment (Net)384.35K268.54K516.58K266.96K275.86K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets000267.26K0
Total Non-current Assets384.35K268.54K516.58K534.22K275.86K
Total Assets233.14M181.29M148.33M104.61M72.06M
Account Payables1.02M133.63K1.34M180.45K158.46K
Short-term Debt229.61K911.76K15.15M31.37K15.25M
Tax Payables00000
Deferred Revenue0006M6M
Other Current Liabilities1.51M3.82M3.09M4.33M4.27M
Total Current Liabilities11.77M15.36M22.26M18.6M27.81M
Long-term Debt15.5M14.92M015M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)006M00
Other Non-current Liabilities00000
Total Non-current Liabilities15.63M14.92M6.27M15M0
Total Liabilities27.4M30.28M28.53M33.6M27.81M
Common Stock58.08K58.56K59.2K59.65K60.16K
Retained Earnings(294.69M)(356.72M)(394.26M)(450.11M)(483.96M)
Accumulated OCI0(103.94K)037.44K0
Other Stockholders Equity00000
Minority Interest00000
Total Equity205.74M151.01M119.8M71M44.25M
Total Debt15.86M16.08M15.66M15.3M15.53M
Net Debt(213.93M)(128.34M)(127.17M)(39.22M)(54.51M)

Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.